Research
Hormonal
Tirzepatide has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.
Tirzepatide may be a more effective option for managing HbA1c and body weight in patients compared to existing therapies.
StrongSupportsmedium confidence
Tirzepatide, a novel long-acting glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist (GIP/GLP-1 RA), has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.
Why this rating
Based on the randomized, placebo-controlled study design.
Source
A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
Filip K. Knop et al. · Diabetes Obesity and Metabolism · 2024
rct · n=34Cited 35×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →